We examined the effectiveness of a second exposure to ACCEL, a novel driving training program, on latent hazard anticipation (HA) performance several months after their first exposure.


 Twenty-five participants were randomly assigned to either the Placebo group, the ACCEL-1 group, or the ACCEL-2 group.  Participants returned two to six months following the first session and completed either the placebo program (ACCEL-1 and Placebo groups), or a second dose of training program (ACCEL-2 group), again followed by simulated evaluation drives.


 The ACCEL-2 group showed improved HA performance compared to the ACCEL-1 and Placebo groups in the second evaluation.


 ACCEL enhances young novice drivers' latent HA performance.  The effectiveness of ACCEL is retained up to 6 months, and a second dose further improves HA performance.



ACCEL
Twenty-five participants were randomly assigned to either the Placebo group, the ACCEL-1 group, or the ACCEL-2 group.  Participants returned two to six months following the first session and completed either the placebo program (ACCEL-1 and Placebo groups), or a second dose of training program (ACCEL-2 group), again followed by simulated evaluation drives.


 The ACCEL-2 group showed improved HA performance compared to the ACCEL-1 and Placebo groups in the second evaluation.



ACCEL-1
Twenty-five participants were randomly assigned to either the Placebo group, the ACCEL-1 group, or the ACCEL-2 group.  Participants returned two to six months following the first session and completed either the placebo program (ACCEL-1 and Placebo groups), or a second dose of training program (ACCEL-2 group), again followed by simulated evaluation drives.


 The ACCEL-2 group showed improved HA performance compared to the ACCEL-1 and Placebo groups in the second evaluation.



ACCEL-2